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 The aim of the study was to evaluate the 
spectrum of AIDS-defining malignancies 
(ADMs) and non-AIDS-defining malignan-
cies (NADMs) in HIV-infected patients in 
Poland.
Material and methods: A retrospective ob-
servational study was conducted among 
HIV-infected adult patients who developed 
a malignancy between 1995 and 2012 in 
a Polish cohort. Malignancies were divided 
into ADMs and NADMs. Non-AIDS-defin-
ing malignancies were further categorised 
as virus-related (NADMs-VR) and unrelat-
ed (NADMs-VUR). Epidemiological data 
was analysed according to demographic 
data, medical history, and HIV-related in-
formation. Results were analysed by OR, 
EPITools package parameters and Fisher’s 
exact test.
Results: In this study 288 malignancies 
were discovered. The mean age at diagno-
sis was 41.25 years (IQR20-81); for ADMs 
38.05 years, and for NADMs-VURs 46.42 
years; 72.22% were male, 40.28% were 
co-infected with HCV. The risk behaviours 
were: 37.85% IDU, 33.33% MSM, and 
24.31% heterosexual. Mean CD4+ at the 
diagnosis was 282 cells/mm³ (for ADMs 
232 and for NADMs-VUR 395). Average 
duration of HIV infection at diagnosis was 
5.69 years. There were 159 (55.2%) ADMs 
and 129 (44.8%) NADMs, among whom 
58 (44.96%) NADMs-VR and 71 (55.04%) 
NADMs-VUR. The most frequent malig-
nancies were: NHL (n = 76; 26.39%), KS 
(n = 49; 17.01%), ICC (n = 34; 11.81%), 
HD (n = 23; 7.99%), lung cancer (n = 18; 
6.25%) and HCC (n = 14; 4.86%). The 
amount of NADMs, NADMs-VURs in par-
ticular, is increasing at present. Male gen-
der (OR = 1.889; 95% CI:  1.104–3.233; p = 
= 0.024), advanced age: 50–60 years (OR = 
= 3.022; 95% CI: 1.359–6.720; p = 0.01) 
and ≥ 60 years (OR = 15.111; 95% CI: 
3.122–73.151; p < 0.001), longer duration 
of HIV-infection and successful HAART 
(OR = 2.769; 95% CI: 1.675–4.577; p = 0) 
were independent predictors of NADMs 
overall, respectively. 
Conclusions: In a Polish cohort NHL was 
the most frequent malignancy among 
ADMs, whereas HD was the most fre-
quent among NADMs. Increased inci-
dence of NADMs appearing in elderly men 
with longer duration of HIV-infection and 
with better virological and immunological 
control was confirmed. As HIV-infected 
individuals live longer, better screening 
strategies, especially for NADMs-VUR, are 
needed. The spectrum of cancer diagno-
ses in Poland currently does not appear 
dissimilar to that observed in other Euro-
pean populations.
Key words: HIV, AIDS-defining malig- 
nancies, non-AIDS-defining malignancies, 
PLHIV, cART, cancer.
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Introduction
The prevalence and spectrum of malignancies have continued to grow, re-
sulting in high morbidity and mortality. It also concerns, with no exceptions, 
people living with human immunodeficiency virus (PLHIV) [1–3]. Experience 
has taught us that several malignancies, such as Acquired Immunodeficien-
cy Syndrome-AIDS-defining malignancies (ADMs), including Kaposi sarcoma 
(KS), non-Hodgkin’s lymphoma (NHL), and an invasive cervical cancer (ICC) 
are closely connected with human immunodeficiency virus (HIV) infection 
and are found more frequently in HIV-infected patients. Since the intro-
duction of combination antiretroviral therapy (cART), the number of ADMs 
as a whole has decreased significantly. Nevertheless, it remains a signifi-
cant problem and one of the major causes of death [4–6]. There also exist 
non-AIDS-defining malignancies (NADMs), the number of which seems still 
to be rising and the reasons for which may be completely different [7–13]. 
NADMs appear to have increased prevalence and higher malignancy-related 
mortality attributable to earlier onset, a more advanced malignancy stage, 
and a worse prognosis at malignancy diagnosis in HIV-infected patients than 
in the general population [9–10, 14–17]. Although the introduction of cART 
has considerably improved HIV positive patients’ prognosis and contributed 
to a significant decrease of opportunistic infections prevalence and mor-
tality, NADMs have become responsible for a new challenge in HIV-positive 
patients’ care and cure. It is still unclear whether the number of NADMs has 
indeed increased or whether their prevalence is the result of both increased 
surveillance and longevity of HIV-positive patients [18–19]. Furthermore, 
there are many possible reasons and risk factors of NADMs prevalence in 
HIV-infected individuals. The rise in survival caused by cART may also result 
in an increased exposure of the population to oncogenes, including, among 
others, HIV chronic infection, prolonged immunosuppression, environmental 
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factors, and potentially oncogenic drug activities [7–9, 15, 
20–22]. We should also take into consideration the life-
style of many PLHIV and the impact of an increased bur-
den of traditional risk factors, such as, for example, smok-
ing [18, 23]. Moreover, co-infections with other viruses and 
their treatment have also influenced the carcinogenesis 
in HIV-infected individuals with the loss of immune con-
trol. Thus, literature often tends to make a distinction be-
tween virus related (VR) NADMs and virus unrelated (VUR) 
NADMs [20, 24]. Some viruses have specific oncogenic 
properties. For instance, the relation between human pap-
illomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus 
(HCV), human herpesvirus-8 (HHV-8), Epstein-Barr virus 
(EBV), and malignancies has been confirmed [9, 24–26]. In 
addition, Immune Reconstitution Inflammatory Syndrome 
in successful antiretroviral treatment (ART) induces the 
activity of latent oncogenic viruses [27]. Much remains to 
be learned about the risk of malignancies onset, risk re-
duction, optimal treatment, and drug interactions in the 
HIV-infected population. The aim of this study was to eval-
uate the spectrum of malignancies in HIV-infected adult 
population (18 years and older) in Poland; to describe the 
trends in these illnesses over the past eighteen years; and 
to attempt to research the reasons for their hypothetically 
increased prevalence. 
Material and methods 
There is limited data of malignancies’ prevalence in 
HIV-infected patients in Poland. The very first retrospective, 
observational study was conducted among HIV-infected 
adult patients who developed a malignancy during the pe-
riod 1995–2012 in the long-lasting Polish cohort approach. 
The present analysis is based upon the data collected from 
1st January 1995 to the earliest diagnosis of a new malig-
nancy, namely until 1st January 2013 (the cut-off date for 
the present dataset), adding the observational period of 
six months after the patient’s last clinic visit. HIV-database 
includes most (8 out of 10) of AIDS clinical centres that also 
offer ART in Poland: Białystok, Bydgoszcz, Gdańsk, Kraków, 
Łódź, Poznań, Szczecin, and Warszawa. The malignancies 
were classified according to the current World Health Or-
ganisation (WHO), International Statistical Classification of 
Diseases and Related Health Problems, the tenth edition 
code classification system (ICD-10), including the WHO 
Classification of Tumours of Hematopoietic and Lymphoid 
Tissues for HIV-related lymphomas [28, 29]. Detailed data 
on all malignancies was collected on a specific and anon-
ymous case report form (CRF). The CRFs have also includ-
ed a definite histological confirmation or, exceptionally, 
through lack of other measures, a case description based 
upon an accurate clinical diagnosis and complementary 
examinations made by an experienced practitioner where 
the treatment had been initiated to support the descrip-
tion of an invasive malignancy, yet lacking supportive his-
topathological findings. A probable degree of certainty was 
excluded from the study. All patients diagnosed with ma-
lignancies were followed up by an oncologist. Malignancies 
were divided into ADMs and NADMs. Additionally, NADMs 
were further categorised as virus-related (NADMs-VR) and 
virus unrelated (NADMs-VUR). Epidemiological data was 
analysed according to demographic data, medical history, 
HIV-related information, ART, and malignancies’ outcome, 
and was collected from all patients at the time of malig-
nancy diagnosis. The contact with HBV was defined as 
HBV surface antigen positive. The contact with HCV was 
defined as HCV core antibody positive at baseline or ever in 
the past. Baseline characteristics of the patients are sum-
marised in Table 1, stratified by separate malignancy types. 
A standard descriptive analysis was performed, including 
frequency distributions for categorical data and calculation 
of medians alongside interquartile ranges (IQR) for contin-
uous variables. The predictors of declining screening were 
explored using univariate and multivariate logistic regres-
sion. The parameters Odds Ratio (OR) and 95% confidence 
limits (95% Cl) were reported in the analysis of the associa-
tion of chosen attributes in various types of cancers (ADMs 
vs. NADMs and NADMs-VR vs. NADMs-VUR). The system R 
and packet EPITools of the function Epitab were used for 
data calculation. The Fisher’s exact test was used to cal-
culate the p-value. Specific ethical approval for this study 
was not a requirement, in accordance with Polish national 
legislation.
Results 
In this study, between 1995 and 2012, a total of 288 
malignancies were finally confirmed in 285 HIV-infected 
adult patients and were ultimately included in the anal-
yses. One patient diagnosed with NADM was previously 
diagnosed with an ADM, and two patients were diagnosed 
with two malignancies from the same group; however, 
they occurred at different times. In the vast majority of the 
cases, the malignancies were confirmed by histological ex-
amination (n = 260; 90.3%) and the rest were defined as 
the probable degree of certainty as mentioned above (n = 
= 28; 9.7%). Table 1 gives the main characteristics of pa-
tients included in the present study. The mean age at the 
malignancy diagnosis was 41 years [IQR, 20–81 years]; the 
youngest for ADMs was 38 years and the most advanced 
for NADMs-VURs was 46 years. Patients were mainly male 
(n = 208; 72.2%) and of white ethnic origin (n = 284; 98.6% 
Caucasian). Overall, the risk behaviours reported were as 
follows: 37.8% Injecting Drug Users (IDUs; n = 109), 33.3% 
Men who have Sex with Men (MSM; n = 96), and 24.3% 
heterosexual (n = 70), and they were broadly similar to 
each group of malignancies. Men who have Sex with Men 
dominated solely in the ADMs group (n = 61; 38.4%) where 
KS diagnosed patients constituted 75.5% (n = 37). HIV-in-
fected patients diagnosed with malignancies had, in the 
majority, smoked tobacco at some time (n = 216; 75%) and 
they had high prevalence of co-infections with HBV (n = 
= 105; median 36.5%) and HCV (n = 116; median 40.3%). 
Most of the patients showed advanced HIV disease. In 
almost one third of the patients (n = 90; 31.3%) HIV in-
fection diagnosis was confirmed at the same time or less 
than a year before a malignancy diagnosis. As much as 
41.5% (n = 66) of the patients diagnosed with ADM were 
late presenters. Moreover, most of them were previously 
diagnosed with AIDS – over two third of them (n = 219; 
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Table 1. Characteristics of the patients at the time of malignancies’ diagnosis, for all malignancies in total and for each group: ADMs, 
NADMs, NADMs-VR, NADMs-VUR
Characteristics
(n = 288):
Total (n = 288)
n (%)
ADMs (n = 159)
n (%)
NADMs (n = 129)
n (%)
NADMs-VR (n = 58)
n (%)
NADMs-VUR (n = 71)
n (%)
Age at baseline
median [IQR] (years) 41 [20-81] 38 [21-66] 45 [20-81] 44 [22-71] 46 [20-81]
Gender
male
female
208 (72.2)
80 (27.8)
106 (66.7)
53 (33.3)
102 (79.1)
27 (20.9)
50 (86.2)
8 (13.8)
52 (73.2)
19 (26.8)
Race
Caucasian
other
284 (98.6)
4 (1.4)
156 (98.1)
3 (1.9)
129 (100.0)
0 (0.0)
58 (100.0)
0 (0.0)
70 (98.6)
1 (1.4)
Exposure group
homosexual
IDU
hetreosexual
other
96 (33.3)
109 (37.8)
70 (24.3)
13 (4.5)
61 (38.4)
54 (34.0)
38 (23.9)
6 (3.8)
35 (27.1)
55 (42.6)
32 (24.8)
7 (5.4)
17 (29.3)
28 (48.3)
11 (19.0)
2 (3.4)
18 (25.4)
27 (38.0)
21 (29.6)
5 (7.0)
Hepatitis B status
negative
positive
unknown
182 (63.2)
105 (36.5)
1 (0.3)
107 (67.3)
51 (32.1)
1 (0.6)
75 (58.1)
54 (41.9)
0 (0.0)
36 (62.1)
22 (37.9)
0 (0.0)
39 (54.9)
32 (45.1)
0 (0.0)
Hepatitis C status
negative
positive
unknown
167 (58.0)
116 (40.3)
5 (1.7)
97 (61.0)
58 (36.5)
4 (2.5)
70 (54.3)
58 (45.0)
1 (0.8)
27 (46.6)
31 (53.4)
0 (0.0)
43 (60.6)
27 (38.0)
1 (1.4)
Ever smoked
yes
no
216 (75.0)
72 (25.0)
114 (71.7)
45 (28.3)
102 (79.1)
27 (20.9)
46 (79.3)
12 (20.7)
56 (78.9)
15 (21.1)
Ever abused alcohol
yes
no
129 (44.8)
159 (55.2)
74 (46.5)
85 (53.5)
55 (42.6)
74 (57.4)
31 (53.4)
27 (46.6)
24 (33.8)
47 (66.2)
Ever abused drugs
yes
no
112 (38.9)
176 (61.1)
57 (35.8)
102 (64.2)
55 (42.6)
74 (57.4)
29 (50.0)
29 (50.0)
26 (36.6)
45 (63.4)
Duration of HIV-infection (years)
< 1
1-5
6-10
> 10
90 (31.3)
85 (29.5)
46 (16.0)
67 (23.3)
66 (41.5)
46 (28.9)
22 (13.8)
25 (15.7)
24 (18.6)
39 (30.2)
24 (18.6)
42 (32.6)
10 (17.2)
16 (27.6)
14 (24.1)
18 (31.0)
14 (19.7)
23 (32.4)
10 (14.1)
24 (33.8)
Prior opportunistic infections
yes
no
127 (44.0)
161 (55.9)
61 (38.4)
98 (61.6)
66 (51.2)
63 (48.8)
35 (60.3)
23 (39.7)
31 (43.7)
40 (56.3)
Nadir CD4 count
median [IQR] (cells/mm³) 145 [0-1265] 135 [0-1265] 157 [2-965] 131 [2-426] 179 [2-965]
CD4 count at baseline
median [IQR] (cells/mm³) 282 [8-1265] 232 [3-1265] 345 [8-1260] 283 [8-1260] 395 [18-1242]
VL suppression at baseline 
(< 50 copies/ml)
yes
no
unknown
89 (30.9)
175 (60.8)
24 (8.3)
32 (20.1)
109 (68.6)
18 (11.3)
57 (44.2)
66 (51.2)
6 (4.7)
25 (43.1)
28 (48.3)
5 (8.6)
31 (43.7)
39 (54.9)
1 (1.4)
Ever started cART before 
malignancies’ diagnosis
yes
no
150 (52.1)
138 (47.9)
70 (44.0)
89 (56.0)
80 (62.0)
49 (38.0)
33 (56.9)
25 (43.1)
47 (66.2)
24 (33.8)
cART at baseline
yes
no
139 (48.3)
149 (51.7)
63 (39.6)
96 (60.4)
76 (58.9)
53 (41.1)
33 (56.9)
25 (43.1)
43 (60.6)
28 (39.4)
Duration of cART (years) none
< 1 
1-2
3-5
> 5
138 (47.9)
48 (16.7)
33 (11.5)
23 (8.0)
46 (16.0)
89 (56.0)
33 (20.8)
18 (11.3)
8 (5.0)
11 (6.9)
49 (38.0)
15 (11.6)
15 (11.6)
15 (11.6)
35 (27.1)
25 (43.1)
6 (10.3)
7 (12.1)
6 (10.3)
14 (24.1)
24 (33.8)
9 (12.7)
8 (11.3)
9 (12.7)
21 (29.6)
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76.0%) had nadir CD4+ cell count < 200 cells/mm³ (Cen-
tres for Disease Control and Prevention (CDC) classifica-
tion system-clinical categories 3) and/or almost half of the 
patients (n = 127; 44%) had experienced at least one of 
the opportunistic infections (not including ADMs) before 
the baseline (CDC classification system – clinical catego-
ries C). An average duration of HIV infection before the 
diagnosis was short, averaging 5.7 years. Attention shall 
be paid to a longer period of HIV infection among NADMs, 
particularly among the NADMs-VR. Mean nadir CD4+T 
cell count was 145 cells/mm³ (the lowest for NADMs-VR 
131 cells/mm³ and the highest for NADMs-VUR 179 cells/
mm³). The average duration of cART according to accurate 
Polish guidelines before malignancies’ diagnosis was also 
short and was equal to 1.9 years (the shortest for ADMs 
was 1.0 year and the longest for NADMs-VUR was 3.2 
years). Mean CD4+T cell count at baseline was 282 cells/
mm³ (the lowest for ADMs was 232 cells/mm³ and the 
highest for NADMs-VUR was 395 cells/mm³) and 60.8% 
(n = 175) patients at baseline had a detectable HIV-1 viral 
load (> 50 copies/ml). As much as 60.4% (n = 96) of the 
patients had not received any cART when ADM was diag-
nosed, unlike 58.9% (n = 76) of the patients who received 
such treatment when NADM was diagnosed, most of all at 
the NADM-VUR diagnosis (n = 43; 60.6%). The diagnosis 
of any malignancy was connected to a worse prognosis 
and poor treatment outcome with mean overall survival 
after malignancies’ diagnosis equal to 3.4 years – short-
est for NADMs-VUR at 2.5 years. Although for 80.2% (n = 
= 231) of the patients, oncological treatment was started, 
as much as 45.1% (n = 130) of them died during the obser-
vation period, while the highest mortality was registered 
for NADMs-VR (n = 33; 56.9%). For as much as 92.9% of 
the patients diagnosed with hepatocellular carcinoma 
(HCC) (n = 13/14) symptomatic treatment was introduced 
due to the advanced stage of the malignancy and the lack 
of any possibility to start curative treatment. Similarly, the 
palliative treatment was started for 55.6% (n = 5/9) of pri-
mary central nervous system lymphomas (PCNSLs) and 
33.3% of lung cancers (n = 6/18). 
There were 159 (55.2%) ADMs and 129 (44.8%) NADMs 
diagnosed. Among NADMs 58 (45%; 20.1% of total malig-
nancies) were VR and 71 (55%; 24.7% of total malignan-
cies) were VUR. Figure 1 shows that the cumulative inci-
dence of malignancies increased considerably in each of 
the three six-year periods from 1995 to 2012. However, it 
should also be emphasised that a progressive, substantial 
increase in the 6-year cumulative incidence was chiefly ob-
served for NADMs. Furthermore, this figure demonstrates 
a rising trend in NADMs-VUR among NADMs over the 
study period.
Most of the cases were as follows: non-Hodgkin lym-
phoma (NHL) (n = 76; 26.4%), Kaposi sarcoma (KS) (n = 
= 49; 17.0%), invasive cervical cancer (ICC) (n = 34; 11.81%), 
Hodgkin’s disease (HD) (n = 23; 8.0%), lung cancer (n = 18; 
6.3%), and hepatocellular carcinoma (HCC) (n = 14; 4.9%). 
The most frequent malignancies classified by sex were as 
follows: NHL (n = 57; 27.4%), KS (n = 49; 23.6%), HD (n = 
= 19; 9.1%), lung cancer (n = 17; 8.2%) for men and ICC (n = 
= 34; 42.5%), NHL (n = 19; 23.8%), HD (n = 4; 5.0%), skin 
cancer (n = 4; 5.0%) for women. The spectrum of con-
firmed malignancies from each group is represented by 
a percentage against the total sum, and they were divid-
ed into sexes (Table 2). Taking into consideration the fre-
quency of particular types of malignancies’ prevalence in 
certain periods of time, most of malignancies increased, 
ADMs – AIDS-defining malignancies; NADMs – non-AIDS-defining malignancies; NADMs-VR – non-AIDS-defining malignancies virus related; NADMs-VUR – non-
AIDS-defining malignancies virus unrelated
Characteristics
(n = 288):
Total (n = 288)
n (%)
ADMs (n = 159)
n (%)
NADMs (n = 129)
n (%)
NADMs-VR (n = 58)
n (%)
NADMs-VUR (n = 71)
n (%)
Death during study period
yes
no
130 (45.1)
158 (54.9)
66 (41.5)
93 (58.5)
64 (49.6)
65 (50.4)
33 (56.9)
25 (43.1)
31 (43.7)
40 (56.3)
Overall survival after 
malignancies’ diagnosis (years)
< 1
1-2
3-5
6-10
> 10
99 (34.4)
66 (22.9)
56 (19.4)
46 (16.0)
21 (7.3)
55 (34.6)
32 (20.1)
27 (17.0)
27 (17.0)
18 (11.3)
44 (34.1)
34 (26.4)
29 (22.5)
19 (14.7)
3 (2.3)
27 (46.6)
7 (12.1)
11 (19.0)
10 (17.2)
3 (5.2)
17 (23.9)
27 (38.0)
18 (25.4)
9 (12.7)
0 (0.0)
Table 1. cont. Characteristics of the patients at the time of malignancies’ diagnosis, for all malignancies in total and for each group: ADMs, 
NADMs, NADMs-VR, NADMs-VUR
Fig. 1. Estimated prevalence of AIDS-defining malignancies (ADMs) 
and non-AIDS-defining malignancies (NADMs). The latter are divid-
ed into virus related (NADMs-VR) and virus unrelated (NADMs-VUR) 
over the presented periods of time 
ADMs 28 64 77
NADMs 10 38 81
NADMs-VR 6 22 30
NADMs-VUR 4 16 51
 1995–2000 2001–2006 2007–2012
90
80
70
60
50
40
30
20
10
0
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especially among NADMs – lung, skin, and anal cancer as 
well as among HD and HCC. The only types of malignan-
cies which showed a tendency to decrease were ICCs and 
PCNSLs. 
On closer inspection of the ADMs and NADMs, mul-
tivariate statistical analysis eventually revealed that pa-
tients diagnosed with NADM were more often male (p = 
= 0.024) and of advanced age: 50–60 years (p = 0.01) and 
≥ 60 years (p < 0.001). Also, the probability of NADMs prev-
alence among patients who had been diagnosed with pri-
or opportunistic infections other than ADM is statistically 
significant and is associated with an increased NADMs 
risk (p = 0.032). Besides, a longer history of HIV-infection 
(1–5 years: p = 0.009; 5–10 years: p = 0.004; > 10 years: 
p < 0.001) and successfully received cART currently (p = 
= 0.003) alongside HIV-1 viral load suppression (p < 0.001) 
and with higher levels of CD4+T cell count (CD4+ > 501 
cells/mm³ vs. ≤ 500 cells/mm³: p < 0.001) at baseline were 
independent predictors of NADMs, respectively. Compar-
ing NADMs-VR and NADMs-VUR, fewer factors remained 
statistically significant, namely: nadir CD4+ count > 500 
cells/mm³ (p = 0.03) and previous or current alcohol abuse 
(p = 0.032) were independent predictors of NADMs-VUR. 
Moreover, for patients diagnosed with NADM-VUR there is 
Type of malignancies (288 evaluable data sets from 285 patients) Total, n Total, % Men, n   Women, n  
Grand total 288 100.0 208 (72.22%) 80 (27.78%)
AIDS-Defining Malignancies (ADMs) – subtotal:
Non-Hodgkin’s Lymphoma (NHL)
Diffuse large B-cell lymphoma (DLBCL):
DLBCLs
Primary central nervous system lymphoma (PCNSL)
Centroblastic lymphoma
Burkitt lymphoma
Plasmablastic lymphoma (PBL)
Kaposi Sarcoma (KS)
Invasive Cervical Cancer (ICC)
159
76
55
42
9
4
18
3
49
34
55.2
26.4
19.1
14.6
3.1
1.4
6.3
1.0
17.0
11.8
106 (66.7%)
57
40
34
3
3
15
2
49
0
53 (33.3%)
19
15
8
6
1
3
1
0
34
Non-AIDS-Defining Malignancies (NADMs) – subtotal:
Non-AIDS-Defining Malignancies-Virus Related (NADMs-VR):
EBV-related:
Hodgkin’s disease (HD)
T-cell non-Hodgkin’s lymphoma
Not classified
HPV-related:
Anal
Larynx
Tonsil
HBV and HCV-related:
Hepatocellular carcinoma (HCC)
Non-AIDS-Defining Malignancies-Virus Unrelated (NADMs-VUR)
Lung
Skin cancer
Germ cell tumor
Colon
Prostate
Thyroid
Acute promyelocytic leukemia
Central nervous system
Ovary
Brest
Uterus
B-cell chronic lymphocytic leukemia
Gallbladder
Multiple myeloma
Stomach
Suprarenal gland
129
58
28
23
3
2
16
9
5
2
14
14
71
18
13
7
5
5
5
3
3
3
2
2
1
1
1
1
1
44.8
20.1
9.7
8.0
1.0
0.7
5.6
3.1
1.7
0.7
4.9
4.9
24.7
6.3
4.5
2.4
1.7
1.7
1.7
1.0
1.0
1.0
0.7
0.7
0.3
0.3
0.3
0.3
0.3
102 (79.1%)
50 (86.2%)
24
19
3,0
2,0
13
8
4
1
13
13
52 (73.2%)
17
9
7
3
5
3
1
2
0
0
0
1
1
1
1
1
27 (20.9%)
8 (13.8%)
4
4
0
0
3
1
1
1
1
1
19 (26.8%)
1
4
0
2
0
2
2
1
3
2
2
0
0
0
0
0
Table 2. Types of malignancies diagnosed among adult HIV-infected patients in a Poland cohort by total and by overall percentage with 
division into sexes
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a statistical tendency to a shorter life expectancy over a 1-2 
year-long period of time (p = 0.003) and 2–5 years (p = 0.004) 
after a malignancy diagnosis. All characteristics of the pa-
tients at the time of malignancies’ diagnosis as well as their 
statistical relations for ADMs vs. NADMs and for NADMs-VR 
vs. NADMAs-VUR are presented in Tables 3 and 4.
Discussion
Between 1995 and 2012, more than 16,300 cases of 
HIV infections were registered in Poland (data from the 
National Institute of Public Health National Institute of 
Hygiene) [30]. In this retrospective, observational study, 
both the number of registered cases of HIV infections and 
Characteristic ADMs NADMs OR 95% CI p value
n % n %
Sex female
male
53
106
33.3
66.7
27
102
20.9
79.1
1
1.889
–
1.104-3.233
–
0.024
Age at the malignancies’ 
diagnosis
(years)
[20; 30)
[30; 40)
[40; 50)
[50; 60)
[60; 81]
34
65
38
20
2
21.4
40.9
23.9
12.6
01.3
18
22
41
32
16
14.0
17.1
31.8
24.8
12.4
1
0.639
2.038
3.022
15.111
–
0.302–1.351
0.99–4.195
1.359–6.72
3.122–73.151
–
0.252
0.072
0.01
0
Mode of HIV exposure bisexual
heterosexual
IDU
MSM
6
38
54
61
03.8
23.9
34.0
38.4
7
32
55
35
05.4
24.8
42.6
27.1
1
0.722
0.873
0.492
–
0.22–2.367
0.276–2.766
0.153–1.58
–
0.764
1
0.241
Duration of HIV-infection at the
malignancies’ diagnosis (years) 
[0; 1)
[1; 5)
[5; 10)
[10; 34]
66
39
26
28
41.5
24.5
16.4
17.6
24
35
27
43
18.6
27.1
20.9
33.3
1
2.468
2.856
4.223
–
1.284–4.742
1.4–5.826
2.168–8.228
–
0.009
0.004
0
Opportunistic infections before
malignancies’ diagnosis
no
yes
98
61
61.6
38.4
63
66
48.8
51.2
1
1.683
–
1.051–2.694
–
0.032
Nadir CD4 count
(cells/mm³)
[0; 200)
[200; 350)
[350; 500)
[> 500]
126
21
8
4
79.2
13.2
05.0
02.5
93
24
6
6
72.1
18.6
04.7
04.7
1
1.548
1.016
2.032
–
0.813–2.948
0.341–3.028
0.558–7.407
–
0.191
1
0.336
Smoking status no
yes
45
114
28.3
71.7
27
102
20.9
79.1
1
1.491
–
0.863–2.576
–
0.172
Alcohol status no
yes
85
74
53.5
46.5
74
55
57.4
42.6
1
0.854
–
0.535–1.363
–
0.552
Drugs status no
yes
102
57
64.2
35.8
74
55
57.4
42.6
1
1.33
–
0.826–2.141
–
0.274
Hepatitis C status negative
positive
unknown
97
58
4
61.0
36.5
02.5
70
58
1
54.3
45.0
00.8
1
1.386
0.346
–
0.861–2.231
0.038–3.167
–
0.184
0.65
Hepatitis B status negative
positive
unknown
107
51
1
67.3
32.1
00.6
75
54
0
58.1
41.9
0.00
1
1.511
0
–
0.932–2.449
0-NaN
–
0.109
1
CD4+ count at the malignancies’ 
diagnosis (cells/mm³) 
[3; 51)
[51; 501)
[> 501]
38
102
19
23.9
64.2
11.9
15
81
33
11.6
62.8
25.6
1
2.012
4.4
–
1.035–3.912
1.934–10.011
–
0.04
0
cART before malignancies’ 
diagnosis 
no
yes
89
70
56.0
44.0
49
80
38.0
62.0
1
2.076
–
1.293–3.334
–
0.003
VL suppression at the
malignancies’ diagnosis 
no
yes
121
38
76.1
23.9
69
60
53.5
46.5
1
2.769
-
1.675–4.577
-
0
Death during study period no
yes
93
66
58.5
41.5
65
64
50.4
49.6
1
1.387
–
0.869–2.214
–
0.191
Overall survival after 
malignancies’ diagnosis (years)  
[0; 1)
[1; 2)
[2; 5)
[5; 10)
[10; 17]
55
13
42
27
22
34.6
08.2
26.4
17.0
13.8
44
20
38
23
4
34.1
15.5
29.5
17.8
03.1
1
1.923
1.131
1.065
0.227
–
0.862–4.293
0.626–2.043
0.538–2.108
0.073–0.708
–
0.114
0.763
0.863
0.007
Table 3. Characteristics of the patients at the time of malignancies’ diagnosis for AIDS-defining malignancies (ADMs) versus non-AIDS- 
defining malignancies (NADMs). Factors statistically associated with NADMs in bold
OR – odds ratio; 95% CI – 95% confidence limits; cART – combination antiretroviral therapy; VL – viral load 
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the number of malignancies diagnosed in these patients 
have been rising over the given periods of time. Not much 
more than a half (n = 159/288; 55.2%) of the identified cas-
es of malignancy were ADMs, among of which NHL was 
the most commonly reported and remains the common-
est malignancy-related cause of death even in the cART 
era, as well as among men, while ICC was the commonest 
among women. Despite the introduction of cART in the 
mid-1990s, there has been a noticeable downward ten-
dency in Poland over a period of time only applicable to 
two malignancies sets. The first, PCNSL, dominates in pa-
tients with marked immunosuppression and EBV co-infec-
tion, which may indirectly testify to partial improvement 
of earlier HIV diagnosis and of cART access [4, 5, 31, 32]. 
Characteristic NADM-VR 
n              %
NADM-VUR 
n               %
OR 95% CI p 
Sex female
male
8
50
13.8
86.2
19
52
26.8
73.2
1
0.438
–
0.176–1.091
–
0.084
Age at the malignancies’ diagnosis
(years) 
[20; 30)
[30; 40)
[40; 50)
[50; 60)
[60; 81]
7
11
21
15
4
12.1
19.0
36.2
25.9
06.9
11
11
20
17
12
15.5
15.5
28.2
23.9
16.9
1
0.636
0.606
0.721
1.909
–
0.18–2.251
0.196–1.873
0.223–2.335
0.436–8.353
–
0.537
0.412
0.768
0.477
Mode of HIV exposure bisexual
heterosexual
IDU
MSM
2
11
28
17
03.4
19.0
48.3
29.3
5
21
27
18
07.0
29.6
38.0
25.4
1
0.764
0.386
0.424
–
0.127–4.596
0.069–2.16
0.072–2.483
–
1
0.427
0.428
Duration of HIV-infection at the
malignancies’ diagnosis (years)  
[0; 1)
[1; 5)
[5; 10)
[10; 34]
10
15
14
19
17.2
25.9
24.1
32.8
14
20
13
24
19.7
28.2
18.3
33.8
1
0.952
0.663
0.902
–
0.333–2.7271
0.219–2.009
0.329–2.478
–
0.577
1
Opportunistic infections before
malignancies’ diagnosis 
no
yes
23
35
39.7
60.3
40
31
56.3
43.7
1
0.509
–
0.252–1.031
–
0.077
Nadir CD4 count
(cells/mm³)
[0; 200)
[200; 350)
[350; 500)
[> 500]
45
11
2
0
77.6
19.0
03.4
0.00
48
13
4
6
67.6
18.3
05.6
08.5
1
1.108
1.875
Inf
–
0.45–2.725
0.327–10.741
NaN-Inf
–
1
0.68
0.03
Smoking status no
yes
12
46
20.7
79.3
15
56
21.1
78.9
1
0.974
–
0.415–2.286
–
1
Alcohol status no
yes
27
31
46.6
53.4
47
24
66.2
33.8
1
0.445
–
0.218–0.907
–
0.032
Drugs status no
yes
29
29
50.0
50.0
45
26
63.4
36.6
1
0.578
–
0.285–1.17
–
0.153
Hepatitis C status negative
positive
unknown
27
31
0
46.6
53.4
0.00
43
27
1
60.6
38.0
01.4
1
0.547
Inf
–
0.27–1.107
NaN-Inf
–
0.11
1
Hepatitis B status negative
positive
unknown
36
22
0
62.1
37.9
0.00
39
32
0
54.9
45.1
0.00
1
1.343
NaN
–
0.662–2.723
NaN-NaN
–
0.475
1
CD4+ count at the malignancies’ 
diagnosis (cells/mm³)
[3; 51)
[51; 501)
[> 501]
8
40
10
13.8
69.0
17.2
7
41
23
09.9
57.7
32.4
1
1.171
2.629
–
0.388–3.533
0.748–9.239
–
1
0.198
cART before malignancies’ 
diagnosis 
no
yes
25
33
43.1
56.9
24
47
33.8
66.2
1
1.484
–
0.725–3.034
–
0.362
VL suppression at the
malignancies’ diagnosis 
no
yes
32
26
55.2
44.8
37
34
52.1
47.9
1
1.131
–
0.564–2.269
–
0.859
Death during study period no
yes
25
33
43.1
56.9
40
31
56.3
43.7
1
0.587
–
0.292–1.182
–
0.158
Overall survival after 
malignancies’ diagnosis (years)  
[0; 1)
[1; 2)
[2; 5)
[5; 10)
[10; 17]
27
4
11
13
3
46.6
06.9
19.0
22.4
05.2
17
16
27
10
1
23.9
22.5
38.0
14.1
01.4
1
6.353
3.898
1.222
0.529
–
1.816–22.229
1.542–9.853
0.439–3.401
0.051–5.513
–
0.003
0.004
0.795
1
Table 4. Characteristics of the patients at the time of malignancies’ diagnosis for non-AIDS-defining malignancies virus related (NADMs-VR) 
versus non-AIDS-defining malignancies virus unrelated (NADMs-VUR). Factors statistically associated with NADMs-VUR in bold 
OR – odds ratio; 95% CI – 95% confidence limits; cART – combination antiretroviral therapy; VL – viral load
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The second malignancy set, namely ICC, the result of sev-
eral genital HPV types, has been identified as the carcino-
genic precursor and necessary co-factor for ICC (not only 
in women with advanced immunosuppression), and it has 
been decreasing over the periods of time presented in 
this study, the reason for which may be easier access and 
more successful prophylactic programmes, HPV vaccines, 
early diagnosis, and ICC treatment in Poland (mostly yearly 
cervical Pap smear) similarly to other studies [4, 5, 19, 25, 
33]. Like in other studies, KS occurs predominantly among 
men (n = 49/49; 100% of the cases in our study) in whom 
81.6% (n = 40/49) reported male-to-male sex contact as 
the mode of HIV transmission, which was probably con-
nected to the same way and prevalence of HHV-8 known 
to cause of KS [4, 5, 34, 35]. We believe that our findings 
may reflect a considerably changing epidemiological sit-
uation in Poland and may prove this means of HIV trans-
mission to be currently predominant. It might be too early 
to observe a significant decrease in the prevalence of NHL 
and KS, and perhaps the HIV infections are still diagnosed 
too late and in a too advanced phase of infection. In pa-
tients unaware of their HIV status, the ADM is often the 
first opportunistic infection.
Apart from ADMs, the remaining malignancies were ei-
ther NADMs, with a noticeable upward tendency exceed-
ing the number of ADMs at the time. More recent data has 
shown several NADMs, most of all viruses being related to 
HIV-positive patients, to be increasing, similarly to the risk 
seen in transplantation recipients compared to the gen-
eral population, suggesting a link between immune sup-
pression proven in the present study [21]. According to the 
classification of malignancies established hereinbefore, 
55% (n = 71/129) of them are NADMs-VR and 45% (n = 
= 58/129) are NADMs-VUR, among which HD was the pre-
dominant one to be diagnosed in both sexes. It is known 
that EBV indicates its relation with HD, which can testify 
to a large number of co-infections with this virus in Po-
land [36]. Taken as a whole, the recent literature would 
suggest that HIV infection is currently an independent 
risk factor of lung cancer [17, 37]. In the present study, 
lung cancer has been a predominant malignancy among 
NADMs-VUR, most of which were diagnosed in men (n = 
= 17/18; 94.4%), which suggests that HIV itself is a genu-
ine risk factor of lung cancer, and its highest upward ten-
dency among all NADMs proves a current epidemic of the 
malignancy in question [38, 39]. In addition, HIV-positive 
individuals who smoke tobacco are more predisposed to 
die of solid tumour than the general population [38, 40]. 
The association with smoking, on the other hand, may 
reflect the risk behaviour of the people who may engage 
in unprotected sex or drug use, which can also lead to vi-
ral co-infections [23, 40, 41]. In the study, the fact that as 
many as 75.8% (n = 216/285) of HIV-positive patients had 
at some time smoked tobacco and as many as 100% (n  = 
= 18/18) of those with a lung cancer were heavy smokers 
accounts for the increasing risk. However, we did not find 
a statistically significant association of smoking status 
and NADMs-VUR. Among NADMs-VR, HCC is commonly re-
ported (n = 14/58; 4.9% of all malignancies, second place 
after HD) and is likely to remain important in HIV-infected 
populations, particularly in the context of the high level of 
co-infections with HBV and HCV presented in the study 
and associated with higher serum hepatitis DNA/RNA vi-
ral levels, progression to cirrhosis, and more frequent HCC 
with more aggressive course and poorer survival time than 
HIV-negative patients [42–44]. In our study, all the cases of 
HCC were HBV and/or HCV co-infected (64.3%; n = 9/14 
HBV and 92.9%; n = 13/14 HCV; one individual only HBV 
mono-co-infection), and 78.6% (n = 11/14) also suffered 
from cirrhosis. We did not find a statistically significant 
association of HBV or HCV co-infection and NADMs-VR 
either, which may be explained, as in lung cancer, by low 
numbers, but may also be due to the inclusion of other 
malignancies in this analysis, depending on co-infections 
with other viruses. HCC was diagnosed mostly in elderly 
men (median age 47.5 years), men (n = 13/14; 92.9%), IDUs 
mode of acquisition (n = 12/14; 85.7%), after many years 
of the lack of treatment, or inadequate treatment of HBV 
and/or HCV co-infection. Furthermore, HCC was usually 
diagnosed too late, which resulted in poor prognosis. It 
may indirectly testify to the fact that HCC natural history 
progression takes from years to decades to occur owing to 
the former major way of HIV transmission in Poland, being 
intravenous drug injection. Attention should be drawn to 
a relatively increasing number of skin cancers over peri-
ods of time mostly in women (it should be mentioned that 
Caucasians are more predisposed to have skin cancer [7]), 
and few cases of breast cancer in women (n = 2/288; only 
2.5% of all malignancies in women, n = 2/80) and no such 
cases in men. There was also no case of leiomyosarcoma 
in both sexes. Comparing the malignancies’ prevalence be-
tween the countries located in the same region in Europe, 
strikingly few anal cancers have been diagnosed [45, 46]. 
Anal cancer was found mostly in men (88.9%; n = 8/9) and 
homosexuals (77.8%; n = 7/9). It was also diagnosed in 
further stages, showing the general tendency to increase 
in recent years. Similarly, a few cases of colorectal carcino-
ma (only n = 5/288; 1.7%) were diagnosed in surprisingly 
young people (median age 37.4 years), no matter the sex, 
the way of HIV transmission, the immune status, and ART 
or prostate cancer (only n = 5/288; 1.7%, median age 70 
years) [4, 45, 47, 48]. There is a necessity of oncological 
supervision, mostly in the group of patients in question, 
as well as the necessity to introduce successful methods 
of prevention and early treatment. 
In our study, we have also found several predictors of 
NADMs and less of VR vs. VUR subgroup. The results pre-
sented in the final part of the study confirm the findings 
from previous studies [7–9, 11–13, 15, 24]. 
There are some limitations to this study. First, this is 
a retrospective, observational research on any type of ma-
lignancy in HIV-positive adult patients in Poland, without 
a control group. As with all cohort studies, we can only refer 
to the data that we have collected. Our study population 
might not reflect the exact distributions of malignancies 
occurring all over the country with a noticeable predomi-
nance of CRFs from the capital of Poland, being the largest 
HIV care and cure centre. Furthermore, there may be vari-
ations between the level of malignancy, screening mostly 
in earlier periods when there were no functional popula-
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tion-based malignancy registries. The registration of all 
the cases of malignancies in HIV-infected population was 
not accurate enough as the centres are located exclusively 
in urban areas. Also, our distribution between NADMs-VR 
and NADMs-VUR may be debateable. Not all of NADMs-VR 
types are dependent on co-infections with certain viruses 
in the same way. Finally, we did not analyse the types of 
malignancies individually, but in selected groups, which 
might have masked specific data. 
In conclusion, the prevalence of malignancies in an 
ageing and growing HIV-infected adult Polish cohort con-
tinued to grow over the period between 1995 and 2012, 
concerning, in particular, non-AIDS-defining virus unrelat-
ed (NADMs-VUR) malignancies. Non-Hodgkin lymphoma 
(NHL) was the most frequent malignancy among ADMs, 
and Hodgkin’s disease (HD) was the most frequent ma-
lignancy among NADMs-VR, whereas lung cancer was 
the most frequent malignancy among NADMs-VUR. It is 
possible that, with assertive prevention strategies, earlier 
diagnosis of HIV-infection in Poland, and starting cART ad-
equately early among patients with a confirmed HIV diag-
nosis, the incidence of ADMs and NADMs-VR will decrease. 
An increased incidence of NADMs was confirmed in elderly 
men with longer duration of HIV-infection, with better vi-
rological and immunological control and prior AIDS diag-
nosis (defined as prior opportunistic infections, excluding 
ADMs). Effective primary prevention and screening strate-
gies especially for NADMs-VUR as well as early detection 
and treatment of co-infections ought to be included in the 
routine long-term follow-up of the HIV-infected popula-
tion. Further effort to resolve the direct and indirect effects 
of HIV itself on NADMs and prospective data to assess 
the impact of cART on all malignancies management and 
treatment outcomes are urgently needed. Nowadays, the 
spectrum of cancer diagnoses in the adult HIV Poland co-
hort does not appear dissimilar to those noted in other 
Western European populations. 
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